Skip to main content
Article thumbnail
Location of Repository

Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin

By Naila Rabbani, Madhu Varma Chittari, Charles W. Bodmer, Daniel Zehnder, Antonio Ceriello and Paul J. Thornalley


OBJECTIVE The aim of this study was to investigate whether apolipoprotein B100 of LDL suffers increased damage by glycation, oxidation, and nitration in patients with type 2 diabetes, including patients receiving metformin therapy. \ud \ud RESEARCH DESIGN AND METHODS For this study, 32 type 2 diabetic patients and 21 healthy control subjects were recruited; 13 diabetic patients were receiving metformin therapy (median dose: 1.50 g/day). LDL was isolated from venous plasma by ultracentrifugation, delipidated, digested, and analyzed for protein glycation, oxidation, and nitration adducts by stable isotopic dilution analysis tandem mass spectrometry. \ud \ud RESULTS Advanced glycation end product (AGE) content of apolipoprotein B100 of LDL from type 2 diabetic patients was higher than from healthy subjects: arginine-derived AGE, 15.8 vs. 5.3 mol% (P < 0.001); and lysine-derived AGE, 2.5 vs. 1.5 mol% (P < 0.05). Oxidative damage, mainly methionine sulfoxide residues, was also increased: 2.5 vs. 1.1 molar equivalents (P < 0.001). 3-Nitrotyrosine content was decreased: 0.04 vs. 0.12 mol% (P < 0.05). In diabetic patients receiving metformin therapy, arginine-derived AGE and methionine sulfoxide were lower than in patients not receiving metformin: 19.3 vs. 8.9 mol% (P < 0.01) and 2.9 vs. 1.9 mol% (P < 0.05), respectively; 3-nitrotyrosine content was higher: 0.10 vs. 0.03 mol% (P < 0.05). Fructosyl-lysine residue content correlated positively with fasting plasma glucose. Arginine-derived AGE residue contents were intercorrelated and also correlated positively with methionine sulfoxide. \ud \ud CONCLUSIONS Patients with type 2 diabetes had increased arginine-derived AGEs and oxidative damage in apolipoprotein B100 of LDL. This was lower in patients receiving metformin therapy, which may contribute to decreased oxidative damage, atherogenicity, and cardiovascular disease. \ud \u

Topics: QP
Publisher: American Diabetes Association
Year: 2010
OAI identifier:

Suggested articles


  1. (2010). Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. doi
  2. (1996). All About Albumin. doi
  3. (2008). Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev doi
  4. (2005). Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia doi
  5. Diabetic dyslipidaemia: from basic research to clinical practice. doi
  6. (2007). Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract doi
  7. (2003). Fluorometric and Colorimetric Assessment of Thiobarbituric Acid-Reactive Lipid Aldehydes in Biological Matrices. doi
  8. (2005). Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care doi
  9. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications.
  10. Innerarity TL, Bore ´n J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. doi
  11. Kinetics and mechanism of the reaction of metformin with methylglyoxal. doi
  12. (2008). LDL glycated by methylglyoxal to physiological extent in vitro has increased binding of proteoglycan without impairment of LDL receptor binding. Diabetologia
  13. (1997). Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. doi
  14. Measurement of plasma hydroperoxide concentration by FOX-1 assay in conjunction with triphenylphosphine. doi
  15. Metabolism of low-density lipoprotein in familial type-H hyperlipoproteinemia. doi
  16. (2003). Metformin inhibition of glycation processes. Diabetes Metab doi
  17. (1999). Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes doi
  18. (2008). Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther doi
  19. NADPH oxidase of neutrophils elevates o,o -dityrosine cross-links in proteins and urine during inflammation. doi
  20. Non-enzymatic glycation of human serum lipoproteins: elevated epsilon-lysine glycosylated low-density lipoprotein in diabetic patients. doi
  21. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. doi
  22. (2008). NOX enzymes as novel targets for drug development. Semin Immunopathol doi
  23. (2000). Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time: in vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol doi
  24. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. doi
  25. Remnant lipoproteins: measurement and clinical significance. doi
  26. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. doi
  27. The genetics of atherothrombotic disorders: a clinician’s view. doi
  28. (2003). Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans doi
  29. Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phox. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.